Oral administration. Swallow the tablet whole with water. Do not crush, chew, or split the tablet.

Migratol is a selective agonist for 5-HT1B and 5-HT1D serotonin receptors. Activation of these receptors leads to cranial vasoconstriction and inhibition of inflammatory neuropeptide release from trigeminal nerve endings, thereby aborting migraine attacks.

• •Ischemic heart disease (e.g., angina pectoris, history of myocardial infarction)
• •Cerebrovascular syndromes (e.g., stroke, transient ischemic attack)
• •Peripheral vascular disease
• •Uncontrolled hypertension
• •Severe hepatic impairment
• •Concurrent use with MAO inhibitors or within 2 weeks of discontinuing them
• •Concurrent use with other 5-HT1 agonists or ergot-type medications

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Symptoms of overdose include severe vasoconstriction, hypertension, transient ischemic attacks, and other cardiovascular events. Management involves supportive therapy, monitoring of cardiovascular and respiratory function, and symptomatic treatment.

Pregnancy Category C. Use only if potential benefit justifies potential risk to the fetus. Small amounts may pass into breast milk; caution advised, consider discarding milk for 12-24 hours after dose.